Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Active, not recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10537
Shown on this page
12
Current sort
Recently updated
Status scope
Active, not recruiting
Additional filters apply within this recruitment status.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this status page

These controls apply only within Active, not recruiting. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 865–876 of 10,537 matching trials with status Active, not recruiting.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Not applicable Interventional

Acceptability of MBSR for People With HS

NCT07903948
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Mindfulness-Based Stress Reduction
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 1:16 AM EST
Active, not recruiting Not applicable Interventional

Parent Intervention for Psychiatrically-Hospitalized Youth

NCT04797455
View directory record Official record
Conditions
Adolescent - Emotional Problem, Suicide and Self-harm, Parenting
Interventions
DBT-Based Parenting Intervention, Treatment as usual
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 1:16 AM EST
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer

NCT07276789
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
LS301-IT 0.1 mg/kg
Drug
Lead sponsor
Integro Theranostics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Iowa City, Iowa • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 1:16 AM EST
Active, not recruiting Phase 3 Interventional

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

NCT04557059
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radiotherapy, LHRHa, Apalutamide
Radiation · Drug
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
18 Years and older · Male only
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
13
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 1:16 AM EST
Active, not recruiting Phase 1 Interventional

NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

NCT06459869
View directory record Official record
Conditions
Locally Advanced Rectal Cancer (LARC)
Interventions
NG-350A IV administration, Capecitabine oral administration, Radiotherapy
Drug · Radiation
Lead sponsor
Akamis Bio
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Orlando, Florida • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 1:16 AM EST
Active, not recruiting Phase 2 Interventional

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

NCT06544616
View directory record Official record
Conditions
Alzheimer Disease
Interventions
JNJ-64042056, Placebo
Drug
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
55 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Murrieta, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 1:16 AM EST
Active, not recruiting Phase 3 Interventional Results available

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

NCT04544293
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Molgramostim, Placebo, Molgramostim Open-label
Drug
Lead sponsor
Savara Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
16
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 1:16 AM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

NCT04538664
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab, Pemetrexed, Carboplatin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Duarte, California • Orange, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 1:16 AM EST
Active, not recruiting Phase 2Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03466411
View directory record Official record
Conditions
Crohn's Disease
Interventions
Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Guselkumab, Ustekinumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
109
States / cities
Dothan, Alabama • Mobile, Alabama • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 1:16 AM EST
Active, not recruiting Phase 1 Interventional

A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies

NCT04606381
View directory record Official record
Conditions
Neoplasms
Interventions
Ami-LC-MD, Ami-LC, Ami-HC, Ami-HC-CF
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
West Hollywood, California • Indianapolis, Indiana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 1:16 AM EST
Active, not recruiting Phase 3 Interventional Results available

Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer

NCT03186898
View directory record Official record
Conditions
Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
Interventions
Proton Therapy, Photon Therapy
Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
27
States / cities
Atlanta, Georgia • Warrenville, Illinois • Baltimore, Maryland + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 1:16 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

An Empowering Parent Training Intervention to Increase Physical Activity in Preschool Aged Children With Autism

NCT07421830
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD)
Interventions
Wellness Enhancing Physical Activity for Young Children: Parent Version (WE PLAY for Parents)
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 1:16 AM EST